Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	208.67	163.89	71.41	83.08	39.48	74.98
Depreciation & Amortization	37.83	37.77	32.88	1.24	0.19	0.09
Asset Writedown & Restructuring Costs	-	-	81.51	-	-	-
Loss (Gain) From Sale of Investments	-8.17	-5.08	-3.02	0.76	-	-
Stock-Based Compensation	23.04	22.25	14.25	7.91	6.07	6.26
Other Operating Activities	-11.08	-9.95	-16.11	9.33	9.6	-32.19
Change in Accounts Receivable	-8.69	-11.96	-43.08	-3.82	-0.63	4.55
Change in Inventory	-1.31	-3.9	-4.74	1.07	-3.22	-2.69
Change in Accounts Payable	-1.59	1.8	10.82	1.21	-1.49	0.14
Change in Other Net Operating Assets	36.4	44.98	-0.33	15.28	10.36	-6.11
Operating Cash Flow	275.09	239.81	143.6	116.05	60.37	45.03
Operating Cash Flow Growth	39.76%	67.00%	23.74%	92.22%	34.06%	30.11%
Capital Expenditures	-0.37	-0.56	-198.52	-10.03	-1.02	-0.01
Sale (Purchase) of Intangibles	-	-	-81.51	-	-	-
Investment in Securities	-	-	-13.47	19.24	-10	-5
Investing Cash Flow	-0.37	-0.56	-293.5	9.21	-11.02	-5.01
Issuance of Common Stock	16.96	154.52	2.79	9.57	4.1	0.76
Repurchase of Common Stock	-1.33	-0.67	-0.98	-7.14	-12.24	-0.06
Other Financing Activities	-13.24	-13.18	-12.67	-0.74	-	-
Financing Cash Flow	2.39	140.67	-10.86	1.69	-8.14	0.7
Net Cash Flow	277.11	379.92	-160.76	126.95	41.21	40.73
Free Cash Flow	274.72	239.25	-54.92	106.02	59.35	45.02
Free Cash Flow Growth	71.19%	-	-	78.63%	31.82%	30.15%
Free Cash Flow Margin	49.19%	48.66%	-13.79%	49.49%	42.14%	37.81%
Free Cash Flow Per Share	2.17	1.92	-0.48	0.95	0.55	0.42
Cash Interest Paid	1.47	1.4	0.71	-	-	-
Cash Income Tax Paid	73.59	68.45	50.46	7.67	3	2.79
Levered Free Cash Flow	226.09	201.64	-219.49	89.69	42.14	28.96
Unlevered Free Cash Flow	226.09	201.64	-219.49	89.69	42.14	28.96
Change in Working Capital	24.81	30.91	-37.32	13.73	5.02	-4.11

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q